4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
主营:原厂直采,平行进口,授权代理(蚂蚁淘为您服务)
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > dialysis > 顶生系统/人PCSK9(R194A)蛋白,His-Tag/50ug/PCA
商品详细顶生系统/人PCSK9(R194A)蛋白,His-Tag/50ug/PCA
顶生系统/人PCSK9(R194A)蛋白,His-Tag/50ug/PCA
顶生系统/人PCSK9(R194A)蛋白,His-Tag/50ug/PCA
商品编号: PCA
品牌: ACROBiosystems
市场价: ¥39600.00
美元价: 19800.00
产地: 美国(厂家直采)
公司:
产品分类: 透析
公司分类: dialysis
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍
  • Synonym
    PCSK9,FH3,HCHOLA3,LDLCQ1,NARC1,PC9
  • Source
    Human PCSK9 (R194A), His Tag (PCA-H5226) is expressed from human 293 cells (HEK293). It contains AA Gln 31 - Gln 692 (Accession # AAI166619.1).
    Predicted N-terminus: Gln 31
    Request for sequence
  • Molecular Characterization
    Online(Gln 31 - Gln 692) AAI166619.1

    This protein is fused with a polyhistidine tag at the C-terminus. This protein undergoes autocatalytic cleavage to release the pro-peptide and mature chain. The pro-peptide and mature chain are associated through non‑covalent interactions and with a calculated MW of 13.8 kDa and 58.0 kDa respectively. The protein migrates as 17 kDa and 66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation. The R194A mutation results in lower affinity of PCSK9 for LDLR.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Human PCSK9 (R194A), His Tag (Cat. No. PCA-H5226) SDS-PAGE gel

Human PCSK9 (R194A), His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
Human PCSK9 (R194A), His TagHuman PCSK9 (R194A), His Tag (Cat. No. PCA-H5226) ELISA bioactivity

Immobilized Human LDL R, His Tag (Cat. No. LDR-H5224) at 10 μg/mL (100 μL/well) can bind Human PCSK9 (R194A), His Tag (Cat. No. PCA-H5226) with a linear range of 0.078-1.25 μg/mL (QC tested).

Protocol
Bioactivity-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Human LDL R, Fc Tag (Cat. No. LDR-H5254) on Protein A Biosensor, can bind Human PCSK9 (R194A), His Tag (Cat. No. PCA-H5226) with an affinity constant of 3.33 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol
  • Background
    Proprotein convertase subtilisin/kexin type 9 (PCSK9), is an enzyme which in humans is encoded by the PCSK9 gene.This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. This protein plays a major regulatory role in cholesterol homeostasis. PCSK9 binds to the epidermal growth factor-like repeat A (EGF-A) domain of the low-density lipoprotein receptor (LDLR), inducing LDLR degradation. PCSK9 may also have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a rare form of autosomal dominant familial hypercholesterolemia (HCHOLA3).
  • References
    • (1)Seidah NG, et al., 2003, Proc. Natl. Acad. Sci. U.S.A. 100 (3): 928–33.
    • (2)Abifadel, M. et al., 2003, Nat. Genet. 34: 154-156.
    • (3)Dubuc G. et al., 2004, Arterioscler. Thromb. Vasc. Biol. 24 (8): 1454–9.
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

品牌介绍
ACROBiosystems 是一个具有全球范围影响力的生物技术领导品牌,其运营包括了位于北美、 欧洲和亚洲的数家公司, 主要为生命科学研究、生物制药与疫病诊断等行业提供产品、技术服务和临床应用等解决方案,同时致力于在蛋白组学、药物发现和细胞治疗等领域推广面向工业化和临床转化的技术和产品。ACROBiosystems 的业务遍及全球50多个国家和地区,并通过在北美、亚洲、欧洲等世界范围的不同时区设立分支机构以服务于当地客户与经销商。